Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combination of everolimus with dactolisib

Pharmaceutical combination of everolimus with dactolisib

US Patent 10576076 · Granted Mar 3, 2020

Estimated economic value: $26,928,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Rapamycin derivatives2025
Methods of treating non-arteritic anterior ischemic optic neuropathy2025
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor2025
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor2025
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor2025
Rapamycin derivatives2024
Method of treating structural and/or functional cardiac abnormalities by adminis2023
Treatment of cancer using a CD123 chimeric antigen receptor2023
Treatment of cancer using a CD123 chimeric antigen receptor2023
Treatment of cancer using a CD123 chimeric antigen receptor2023
Regulatable chimeric antigen receptor2023
Regulatable chimeric antigen receptor2023